Gilbert Dryden probably only has enough medication to get him through the end of October, his mother, Madison, figures. Seven-month-old Gilbert has a rare genetic condition called Barth syndrome, one ...
Barth syndrome is a rare, X‐linked genetic disorder predominantly caused by mutations in the TAZ gene, which encodes the enzyme tafazzin. Tafazzin is responsible for the remodelling of cardiolipin, a ...
FDA advisors indicated a possible path forward for elamipretide as a treatment for Barth syndrome despite the lack of definitive evidence. On Thursday, the Cardiovascular and Renal Drugs Advisory ...
ORLAND PARK, Ill. (WLS) -- A baby boy in the Chicago area is battling a rare disease and desperately needs a drug treatment for a better life. The drug has not been FDA approved, and it could ...
RALEIGH, N.C. (WNCN) – Parents of children with ultra-rare diseases are encouraging the Food and Drug Administration to act quickly to approve drugs that could treat their conditions and to take into ...
No revised PDUFA target date has been communicated by the FDA. A decision on the New Drug Application for elamipretide for the treatment of Barth syndrome has been delayed again, according to Stealth ...
AURORA, Colo. — Five-month-old Gilbert Dryden is thriving—cooing, smiling and gaining weight after spending the first 80 days of his life in the hospital. But his parents said his progress, and ...
Another ultra-rare therapy will soon be subject to the gaze of an FDA advisory committee, with the fate of more than 200 boys diagnosed with Barth syndrome worldwide in the balance. On Thursday, the ...
NEEDHAM, Mass., April 29, 2025 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biotechnology company focused on the discovery, development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results